JOURNAL CULTUREL GRAFFICIBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL CULTUREL GRAFFICI
Company Title:
Company Description:
Keywords to Search:
Company Address:	27 Boul De York E,GASPE,QC,Canada
ZIP Code: Postal Code:	G4X
Telephone Number:	4183687575
Fax Number:	4186294493
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	140650
USA SIC Description:	MAGAZINES & NEWSPAPERS
Number of Employees:
Sales Amount:	$500,000 to $1 million
Credit History: Credit Report:	Unknown
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
KEGA
JUSTICE ALTERNATIVE JEUNESSE
JOURNAL LE PHARILLON

Next company profile:
JOSEPH, JACQUES
JOSEPH JACQUES COIFF HOMMES
JOSE BERNATCHEZ INC

Company News:

The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Current Issue | New England Journal of Medicine
Explore the current issue of The New England Journal of Medicine (Vol 393 No 21)
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream . . .
Bloodstream infections are associated with substantial morbidity and mortality Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain In a multicenter, non
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Methods In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise
new england journal
5 cm; or T3, >5 cm) — that was treated with mastectomy, an axillary procedure, and systemic therapy Patients were assigned to undergo chest-wall irradiation (40 to 50 Gy; the irradiation group